{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:40:30Z","timestamp":1786736430787,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Urol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/iju.iju_56_19","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T04:57:37Z","timestamp":1561957057000},"page":"189","source":"Crossref","is-referenced-by-count":8,"title":["The resurgence of estrogens in the treatment of castration-resistant prostate cancer"],"prefix":"10.4103","volume":"35","author":[{"given":"P","family":"Venugopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HKrishna","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GG","family":"Laxman Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0970-1591.261936-1","first-page":"67","volume-title":"Developmental estrogenization and prostatic neoplasia","author":"Santti","year":"1994","journal-title":"Prostate"},{"key":"key-10.4103\/0970-1591.261936-2","first-page":"97","volume-title":"Effects of estrogens on the prostate","author":"Thomas","year":"1994","journal-title":"J Androl"},{"key":"key-10.4103\/0970-1591.261936-3","first-page":"825","volume-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"key-10.4103\/0970-1591.261936-4","first-page":"169","volume-title":"A prospective, population-based study of androstenedione, estrogens, and prostatic cancer","author":"Barrett-Connor","year":"1990","journal-title":"Cancer Res"},{"key":"key-10.4103\/0970-1591.261936-5","first-page":"3092","volume-title":"Allelic variants of aromatase and the androgen and estrogen receptors: Toward a multigenic model of prostate cancer risk","author":"Modugno","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0970-1591.261936-6","first-page":"1118","volume-title":"Prospective study of sex hormone levels and risk of prostate cancer","author":"Gann","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0970-1591.261936-7","first-page":"151","volume-title":"Estrogen action: A historic perspective on the implications of considering alternative approaches","author":"Jensen","year":"2010","journal-title":"Physiol Behav"},{"key":"key-10.4103\/0970-1591.261936-8","first-page":"814","volume-title":"Metastases of prostate cancer express estrogen receptor-beta","author":"Lai","year":"2004","journal-title":"Urology"},{"key":"key-10.4103\/0970-1591.261936-9","first-page":"81","volume-title":"The evolving role of estrogen therapy in prostate cancer","author":"Oh","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"key-10.4103\/0970-1591.261936-10","first-page":"75","volume-title":"Estrogens as endogenous genotoxic agents \u2013 DNA adducts and mutations","author":"Cavalieri","year":"2000","journal-title":"J Natl Cancer Inst Monogr"},{"key":"key-10.4103\/0970-1591.261936-11","first-page":"329","volume-title":"Catechol estrogen metabolites and conjugates in different regions of the prostate of noble rats treated with 4-hydroxyestradiol: Implications for estrogen-induced initiation of prostate cancer","author":"Cavalieri","year":"2002","journal-title":"Carcinogenesis"},{"key":"key-10.4103\/0970-1591.261936-12","first-page":"S4","volume-title":"The role of estrogens in prostate carcinogenesis: A rationale for chemoprevention","author":"Bosland","year":"2005","journal-title":"Rev Urol"},{"key":"key-10.4103\/0970-1591.261936-13","first-page":"1192","volume-title":"Effect of orchiectomy and irradiation on cancer of the prostate","author":"Huggins","year":"1942","journal-title":"Ann Surg"},{"key":"key-10.4103\/0970-1591.261936-14","doi-asserted-by":"crossref","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40.","DOI":"10.3322\/canjclin.22.4.232"},{"key":"key-10.4103\/0970-1591.261936-15","first-page":"1011","volume-title":"The Veterans Administration Co-Operative Urological Research Group","author":"Treatment","year":"1967","journal-title":"Surg Gynecol Obstet"},{"key":"key-10.4103\/0970-1591.261936-16","first-page":"257","volume-title":"Estrogen treatment for cancer of the prostate.Early results with 3 doses of diethylstilbestrol and placebo","author":"Bailar","year":"1970","journal-title":"Cancer"},{"key":"key-10.4103\/0970-1591.261936-17","first-page":"1126","volume-title":"Proceedings: The veterans administration cooperative urological research group's studies of cancer of the prostate","author":"Byar","year":"1973","journal-title":"Cancer"},{"key":"key-10.4103\/0970-1591.261936-18","first-page":"244","volume-title":"Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer","author":"Montgomery","year":"2010","journal-title":"BMC Cancer"},{"key":"key-10.4103\/0970-1591.261936-19","first-page":"4","volume-title":"Diethylstilboestrol for the treatment of prostate cancer: Past, present and future","author":"Turo","year":"2014","journal-title":"Scand J Urol"},{"key":"key-10.4103\/0970-1591.261936-20","first-page":"52","volume-title":"Effective testosterone suppression for prostate cancer: Is there a best castration therapy?","author":"Gomella","year":"2009","journal-title":"Rev Urol"},{"key":"key-10.4103\/0970-1591.261936-21","first-page":"1259","volume-title":"2 methoxyestradion induces G2\/M arrest and apoptosis in prostate cancer","author":"Qadan","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.4103\/0970-1591.261936-22","first-page":"257","volume-title":"A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer","author":"Smith","year":"1998","journal-title":"Urology"},{"key":"key-10.4103\/0970-1591.261936-23","first-page":"108","volume-title":"The role of diethylstrilbesteron in the treatment of prostate cancer","author":"Malkowicz","year":"2001","journal-title":"Urology"},{"key":"key-10.4103\/0970-1591.261936-24","first-page":"E727","volume-title":"Diethylstilbestrol in castration-resistant prostate cancer","author":"Wilkins","year":"2012","journal-title":"BJU Int"},{"key":"key-10.4103\/0970-1591.261936-25","first-page":"E826","volume-title":"Current role of diethylstilbestrol in the management of advanced prostate cancer","author":"Bosset","year":"2012","journal-title":"BJU Int"},{"key":"key-10.4103\/0970-1591.261936-26","first-page":"428","volume-title":"Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: Retrospective analysis of a single institution experience","author":"Grenader","year":"2014","journal-title":"Oncol Rep"},{"key":"key-10.4103\/0970-1591.261936-27","first-page":"E71","volume-title":"The mechanism of action of estrogen in castration-resistant prostate cancer: Clues from hormone levels","author":"Aggarwal","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"key-10.4103\/0970-1591.261936-28","first-page":"1079","volume-title":"Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer","author":"Omlin","year":"2013","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0970-1591.261936-29","doi-asserted-by":"crossref","unstructured":"Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, et al. Amulti-centre randomised phase III trial of dexamethasone vs. dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs. deferred diethylstilbestrol. Br J Cancer 2011;104:620-8.","DOI":"10.1038\/bjc.2011.7"},{"key":"key-10.4103\/0970-1591.261936-30","first-page":"98","volume-title":"Oral ethinylestradiol in castration-resistant prostate cancer: A 10-year experience","author":"Sciarra","year":"2015","journal-title":"Int J Urol"},{"key":"key-10.4103\/0970-1591.261936-31","first-page":"328","volume-title":"Parenteral estrogen v\/s total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality","author":"Hedlund","year":"2000","journal-title":"Urology"},{"key":"key-10.4103\/0970-1591.261936-32","first-page":"697","volume-title":"Parenteral oestrogen in the treatment of prostate cancer: A systematic review","author":"Norman","year":"2008","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0970-1591.261936-33","first-page":"42","volume-title":"Androgen deprivation therapy and the re-emergence of parenteral estrogen in prostate cancer","author":"Phillips","year":"2014","journal-title":"Oncol Hematol Rev"},{"key":"key-10.4103\/0970-1591.261936-34","first-page":"442","volume-title":"Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer","author":"Langley","year":"2008","journal-title":"BJU Int"},{"key":"key-10.4103\/0970-1591.261936-35","first-page":"CR260","volume-title":"Transdermal estradiol in castrate and chemotherapy resistant prostate cancer","author":"Stein","year":"2012","journal-title":"Med Sci Monit"},{"key":"key-10.4103\/0970-1591.261936-36","first-page":"1735","volume-title":"Transdermal estradiol therapy for advanced prostate cancer \u2013 Forward to the past?","author":"Ockrim","year":"2003","journal-title":"J Urol"},{"key":"key-10.4103\/0970-1591.261936-37","first-page":"498","volume-title":"Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: A mechanism for cardiovascular toxicity and benefit?","author":"Ockrim","year":"2006","journal-title":"BJU Int"},{"key":"key-10.4103\/0970-1591.261936-38","first-page":"306","volume-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: The randomised, phase 2 MRC PATCH trial (PR09)","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0970-1591.261936-39","first-page":"1016","volume-title":"Arandomised comparison evaluating changes in bone mineral density in advanced prostate cancer: Luteinising hormone-releasing hormone agonists versus transdermal oestradiol","author":"Langley","year":"2016","journal-title":"Eur Urol"},{"key":"key-10.4103\/0970-1591.261936-40","first-page":"667","volume-title":"Quality-of-life outcomes from the prostate adenocarcinoma: TransCutaneous hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer","author":"Gilbert","year":"2017","journal-title":"BJU Int"},{"key":"key-10.4103\/0970-1591.261936-41","first-page":"680","volume-title":"Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform","author":"Gilbert","year":"2018","journal-title":"BJU Int"},{"key":"key-10.4103\/0970-1591.261936-42","first-page":"1782","volume-title":"The use of estramustine phosphate in the modern management of advanced prostate cancer","author":"Ravery","year":"2011","journal-title":"BJU Int"},{"key":"key-10.4103\/0970-1591.261936-43","first-page":"177","volume-title":"Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer","author":"Orlando","year":"2000","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0970-1591.261936-44","first-page":"2239","volume-title":"Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer","author":"Smith","year":"2011","journal-title":"J Urol"},{"key":"key-10.4103\/0970-1591.261936-45","first-page":"340","volume-title":"Aphase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer","author":"Zhou","year":"2011","journal-title":"Invest New Drugs"},{"key":"key-10.4103\/0970-1591.261936-46","first-page":"11600","volume-title":"Activation of AKR1C1\/ER\u03b2 induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity","author":"Yun","year":"2015","journal-title":"Oncotarget"},{"key":"key-10.4103\/0970-1591.261936-47","first-page":"31","volume-title":"Managing hot flush in men receiving androgen deprivation therapy for prostate cancer","author":"Khan","year":"2014","journal-title":"Trends Urol Mens Health"},{"key":"key-10.4103\/0970-1591.261936-48","first-page":"132","volume-title":"A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate","author":"Smith","year":"1994","journal-title":"J Urol"},{"key":"key-10.4103\/0970-1591.261936-49","first-page":"97","volume-title":"Transdermal estrogen in the treatment of hot flushes in men with prostate cancer","author":"Gerber","year":"2000","journal-title":"Urology"},{"key":"key-10.4103\/0970-1591.261936-50","first-page":"761","volume-title":"A clinical study of estramustine phosphate sodium for the treatment of hot flushes in men with prostate cancer","author":"Fukuhara","year":"2004","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"key-10.4103\/0970-1591.261936-51","first-page":"100","volume-title":"Re-state of the art treatment in castration-resistant prostate cancer-forward to the past-again","author":"Wilson","year":"2014","journal-title":"EMJ"},{"key":"key-10.4103\/0970-1591.261936-52","first-page":"1731","volume-title":"Cost-effectiveness of androgen suppression therapies in advanced prostate cancer","author":"Bayoumi","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0970-1591.261936-53","first-page":"3595","volume-title":"Avalidated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer","author":"Shamash","year":"2010","journal-title":"Cancer"},{"key":"key-10.4103\/0970-1591.261936-54","first-page":"E921","volume-title":"Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer","author":"Hongo","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"key-10.4103\/0970-1591.261936-55","first-page":"121","volume-title":"A urologist's personal view of prostate cancer","author":"Schellhammer","year":"2016","journal-title":"Turk J Urol"},{"key":"key-10.4103\/0970-1591.261936-56","first-page":"874","volume-title":"Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer","author":"Scher","year":"2017","journal-title":"Eur Urol"},{"key":"key-10.4103\/0970-1591.261936-57","first-page":"1028","volume-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0970-1591.261936-58","first-page":"e223","volume-title":"Delivery of affordable and equitable cancer care in India","author":"Pramesh","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0970-1591.261936-59","first-page":"390","volume-title":"\u201cHealth divide\u201d between indigenous and non-indigenous populations in Kerala, India: Population based study","author":"Haddad","year":"2012","journal-title":"BMC Public Health"}],"container-title":["Indian Journal of Urology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:41:42Z","timestamp":1786732902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/iju.IJU_56_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"alternative-id":["261936"],"URL":"https:\/\/doi.org\/10.4103\/iju.iju_56_19","relation":{},"ISSN":["0970-1591"],"issn-type":[{"value":"0970-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}